Soluble guanylyl cyclase activator / Nitric oxide-independent activator of soluble guanylyl cyclase (sGC). Significantly elevates cGMP levels and inhibits collagen-stimulated aggregation of rabbit platelets (IC50 = 14.6 μM).1 Induces human endometrial cancer cell senescence via modulation of HIF1α activity.2 Induces degradation of HIF1α3 Protects against glutamate-induced neuronal damage4 and -amyloid-induced toxicity in differentiated PC12 cells5.
Biochemicals & reagents
170632-47-0
Lificiguat
1) Martin et al. (2001), YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components; Proc. Natl. Acad. Sci. USA, 98 12938 2) Kato et al. (2006), Induction of human endometrial cancer cell senescence through modulation of HIF-1alpha activity by EGLN1; Int. J. Cancer, 118 1144 3) Kim et al. (2006), A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent; Int. J. Oncol., 29 255 4) Tai et al. (2018), Therapeutic window for YC-1 following glutamate-induced neuronal damage and transient focal cerebral ischemia; Mol. Med. Rep., 17 6490 5) Tsai et al. (2013), The role of heat shock protein 70 in the protective effect of YC-1 on ß-amyloid-induced toxicity in differentiated PC12 cells.; PLoS One, 8(7) e69320
-20°C
TARGET: Guanylyl cyclase -- PATHWAY: Redox; Senescence -- RESEARCH AREA: Neuroscience; Oxidative stress -- DISEASE AREA: Cancer; NeurodegenerationAgeing